Investment Rating - The report maintains a "Buy" rating for the company with a target price based on the last closing price of 134.60 [1][8] Core Insights - The company has seen significant growth in the delivery of its model, the Wanjie M8, with a delivery volume of 12,116 units in May, marking a substantial increase in weekly deliveries [4][5] - The Wanjie M8 has received over 80,000 pre-orders, indicating strong market demand, while the Wanjie M9 has also achieved over 60,000 pre-orders for its 2025 model [5][8] - The establishment of a joint venture for humanoid robot development signals the company's expansion into new growth areas [5][8] Financial Projections - Revenue projections for 2025-2027 are estimated at 189.11 billion, 220.78 billion, and 263.83 billion respectively, with year-on-year growth rates of 30.26%, 16.75%, and 19.50% [8] - The net profit attributable to the parent company is projected to be 10.22 billion, 12.60 billion, and 15.51 billion for the same years, reflecting growth rates of 71.92%, 23.21%, and 23.13% [8] - The diluted earnings per share (EPS) are expected to rise from 3.94 in 2024 to 9.49 in 2027, with a corresponding decrease in price-to-earnings (PE) ratio from 33.86 to 14.23 [8][12] Market Position and Strategy - The company is enhancing its production capacity with a target of 390,000 units by 2024, utilizing advanced manufacturing technologies to reduce costs and improve efficiency [7][8] - The company is also pursuing a global expansion strategy, including plans for an H-share listing to enhance its international competitiveness [7][8]

Investment Rating - The report initiates coverage with a "Buy" rating for the company, targeting a market value of HKD 5.8 billion, which corresponds to a target price of HKD 8.57 [3]. Core Insights - The company has a strong cash flow support from its commercialized product, Selinexor, which has expanded its indications and market presence [2]. - The clinical pipeline includes ATG-022, a differentiated CLDN18.2 ADC, and ATG-037, a CD73 small molecule inhibitor, both showing promising efficacy in treating various cancers [2][3]. - The second-generation TCE platform is expected to enhance safety and efficacy, with the first product, 25H2, submitted for IND [3]. Company Overview - The company focuses on oncology and immunology, with a pipeline that includes one commercialized product and five clinical candidates [8][9]. - Selinexor, the first commercial product, has been approved in multiple Asia-Pacific markets and is expected to see significant revenue growth in 2024 [8][9]. Clinical Pipeline - The company has five clinical-stage assets, including ATG-022 (CLDN18.2 ADC) and ATG-037 (CD73), which are positioned to address unmet medical needs in oncology [11][51]. - ATG-022 has shown efficacy across various CLDN18.2 expression levels in gastric cancer patients, with ongoing clinical trials [34][39]. - ATG-037 is advancing in clinical trials for melanoma and non-small cell lung cancer, demonstrating encouraging safety and efficacy signals [51]. Financial Performance - The company reported a revenue of HKD 92 million in 2024, a 36.7% increase year-on-year, primarily driven by Selinexor's inclusion in the medical insurance directory [23]. - The adjusted annual loss significantly narrowed from HKD 534 million in 2023 to HKD 305 million in 2024, reflecting improved operational efficiency [23]. - Cash reserves at the end of 2024 stood at HKD 900 million, sufficient to support operations for the next three years at the current spending rate [23].

Investment Rating - The report initiates coverage with a "Buy" rating for the company, projecting a target market value of HKD 5.8 billion, corresponding to a target price of HKD 8.57 [3]. Core Insights - The company is positioned as an innovative leader in oncology, focusing on the commercialization of its first product, Selinexor, and advancing its clinical pipeline, including ATG-022 and ATG-037, which show promising efficacy in treating various cancers [2][3]. - Selinexor has already been commercialized and is expected to provide stable cash flow as its indications expand and it enters new markets [3]. - The second-generation T-cell engager (TCE) platform is anticipated to enhance safety and efficacy, with the first product, ATG-201, expected to submit an IND application in the second half of 2025 [3]. Company Overview - The company specializes in oncology and immunology, with a pipeline that includes one commercial product and five clinical-stage assets [8][9]. - Selinexor has been approved in multiple Asia-Pacific markets and is expected to see significant revenue growth in 2024 due to its inclusion in medical insurance [8]. Clinical Pipeline - The clinical pipeline includes ATG-022, a differentiated CLDN18.2 ADC, and ATG-037, a leading CD73 small molecule inhibitor, both of which have shown positive efficacy signals in clinical trials [3][51]. - ATG-022 targets a specific patient population with CLDN18.2 expression and has demonstrated efficacy across various expression levels in gastric cancer patients [34][39]. Financial Performance - The company reported a revenue of HKD 92 million in 2024, a year-on-year increase of 36.7%, primarily driven by Selinexor's sales [23]. - The adjusted annual loss decreased significantly from HKD 534 million in 2023 to HKD 305 million in 2024, reflecting improved operational efficiency [23]. Market Potential - The report highlights the significant market potential for ATG-022, estimating peak sales of approximately HKD 1.2 billion by 2034, driven by its application in both first-line and second-line gastric cancer treatments [42][44]. - The company is well-positioned in a competitive landscape, with multiple ADCs targeting CLDN18.2 currently in clinical trials, indicating a robust market for its products [32][33].

Investment Rating - The report maintains an "Accumulate" rating for Changjiu Logistics (603569) with a target price based on the last closing price of 8.12 [1][6] Core Views - The report highlights that the complete vehicle export business may drive performance growth for Changjiu Logistics in the future [1][6] - The company achieved total operating revenue of 4.17 billion RMB in 2024, representing a year-on-year increase of 10.4%, and a net profit attributable to shareholders of 80 million RMB, up 13.11% year-on-year [4][5] - The logistics core business generated revenue of 4.15 billion RMB in 2024, with a gross profit of 470 million RMB, reflecting a gross profit margin of 97.3% [5] Financial Summary - For 2025 Q1, the company reported revenue of 1.16 billion RMB, a year-on-year increase of 28.2%, while the net profit attributable to shareholders decreased by 74% [4][5] - The company plans to distribute a cash dividend of approximately 30 million RMB for 2024, which corresponds to a dividend yield of about 0.7% based on the stock price at the time of the report [4] - The financial forecast indicates that operating revenue is expected to reach 4.59 billion RMB in 2025, with a year-on-year growth of 10% [7]

Group 1: Market Overview - The bond market is experiencing a general rise, with expectations that it will benefit from inflows of risk-averse capital due to low stock market volatility [4][19]. - The A-share market is showing signs of rotation, with a total trading volume of 1.15 trillion, indicating a focus on consumer sectors and a majority of stocks rising [22]. - The U.S. stock market is in a phase of slight upward movement, with the Dow Jones, S&P 500, and Nasdaq indices increasing by 0.51%, 0.58%, and 0.81% respectively [29]. Group 2: Asset Class Tracking - The bond market is expected to regain upward momentum as risk aversion increases, particularly if stock market volatility rises [4][19]. - The A-share market is characterized by low volatility and a cautious approach is recommended, especially if indices approach the 3000-point mark [22]. - The foreign exchange market shows the onshore RMB appreciating against the USD, with expectations of reaching around 7.1 [33]. Group 3: Sector Insights - Consumer sectors such as beauty care, beverage manufacturing, and textiles are leading the market, but overall trading volume remains insufficient for sustained growth [22]. - The commodity market is experiencing a rebound, with the Wenhua Commodity Index rising by 0.72%, although it is still in a bearish trend overall [36]. - The agricultural and high-dividend sectors are highlighted as having stronger certainty for future performance [22].

Investment Rating - The report maintains a "Buy" rating for the company [1][8] Core Insights - The company has seen significant growth in the delivery of its AITO M8 model, with May deliveries reaching 12,116 units, and a weekly delivery rate exceeding 5,000 units [4][5] - The AITO M8 has received over 80,000 pre-orders, indicating strong market demand [5] - The company is also venturing into humanoid robotics, establishing a joint venture with Beihang University to develop and sell intelligent robots, which is expected to create new growth opportunities [5][8] - The company is planning to issue H-shares to enhance its global presence and competitiveness [7] Financial Projections - Revenue projections for 2025-2027 are estimated at 189.11 billion, 220.78 billion, and 263.83 billion respectively, with year-on-year growth rates of 30.26%, 16.75%, and 19.50% [8] - Net profit forecasts for the same period are 10.22 billion, 12.60 billion, and 15.51 billion, reflecting growth rates of 71.92%, 23.21%, and 23.13% [8] - The report anticipates a diluted earnings per share of 6.26 yuan in 2024, increasing to 9.49 yuan by 2027 [8] Stock Performance Data - The total share capital is 1.633 billion shares, with a market capitalization of 219.85 billion yuan [3] - The stock has seen a 12-month high of 149.89 yuan and a low of 70.24 yuan [3]

Investment Rating - The report assigns an "Accumulate" rating to the company with a target price of 21.00, compared to the last closing price of 20.44 [1]. Core Insights - The company's main business remains stable, and it is advancing its "one core and two wings" development strategy. The focus is on enhancing its weaponry supply system and transitioning its automotive parts business towards electric and integrated solutions [4][5]. - The company has significantly increased its R&D investment, reaching 2.79 billion in 2024, a 36.29% increase year-on-year, indicating a strong commitment to technological innovation [5]. - The financial forecast predicts net profits of 2.67 billion, 2.69 billion, and 2.73 billion for 2025-2027, with corresponding EPS of 0.26 for each year, reflecting a stable growth outlook [5][7]. Financial Performance - In 2024, the company achieved a revenue of 43.55 billion, a 2.32% increase from the previous year, while net profit decreased by 10.70% to 2.60 billion [3][4]. - The projected revenue growth rates for the next three years are 0.50%, 1.50%, and 2.50%, indicating a gradual increase in sales [7]. - The company holds a total market capitalization of 211.15 billion, with a total share capital of 10.33 billion shares [3].

Investment Rating - The industry rating is optimistic, expecting overall returns to exceed the CSI 300 Index by more than 5% in the next six months [12]. Core Viewpoints - The report indicates that the equity market is generally rising, with the Shanghai Composite Index and Shenzhen Composite Index increasing by 0.43% and 0.48% respectively, while the Shenwan Real Estate Index decreased by 0.31% [4]. - The report highlights significant individual stock performances within the real estate sector, with top gainers including Xinda Zheng (10.02%), Nandu Property (9.98%), and Wantong Development (6.63%) [5]. - The report notes that Wuhan is set to auction six land parcels with a total starting price of 1.908 billion yuan, indicating ongoing land supply activities [6]. - The report mentions that the Shanghai Nanxiang CR Land Colorful City project is expected to be sold for approximately 300 to 400 million yuan, reflecting market activity in commercial real estate [7]. - The report states that in 2024, over 1.3 trillion yuan in housing provident fund loans were issued, indicating robust lending activity in the housing sector [7]. Summary by Sections Market Conditions - As of June 3, 2025, the equity market shows a positive trend with most sectors rising, while the real estate index has seen a slight decline [4]. Individual Stock Performance - The top five gainers in the real estate sector are Xinda Zheng (10.02%), Nandu Property (9.98%), Wantong Development (6.63%), Haitai Development (4.23%), and Quzhou Development (3.50%) [5]. - The largest decliners include Nanguo Real Estate (-4.48%), Rongfeng Holdings (-4.28%), Jindi Group (-3.64%), China Merchants Jinling (-3.56%), and Binjiang Group (-3.20%) [5]. Industry News - Wuhan is set to auction six land parcels with a total area of 212,000 square meters and a total starting price of 1.908 billion yuan [6]. - The Shanghai Nanxiang CR Land Colorful City project is expected to be sold for 300 to 400 million yuan [7]. - In 2024, the total amount of housing provident fund loans issued was over 1.3 trillion yuan, with 36,317.83 billion yuan in contributions [7].

宏观 证券研究报告 |点评报告 2025/6/3 5月PMI数据点评—— 供需修复，经济回稳 徐超 S1190521050001 证券分析师： 分析师登记编号： 万琦 S1190524070001 证券分析师： 分析师登记编号： 目录 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 1、制造业PMI温和改善 2、非制造业延续平稳扩张态势 ➢ 中国5月官方制造业PMI49.5，预期49.5，前值49.0。 1、制造业PMI温和改善 ➢制造业PMI边际小幅修复。5月制造业采购经理指数为49.5%，比上月上升0.5个百分点，符合市场预 期，表现好于季节性。经济有所回稳，如期实现温和修复，这一方面得益于国内积极政策的加紧实 施，另一方面也与5月中美日内瓦经贸会谈达成协议、关税冲击有所缓和有关。 ➢多数分项较前值有所反弹。从主要分项指数的边际变化来看，本月除产成品库存指数、购进价格指 数、出厂价格指数和供应商配送时间指数较前值下降外，其余分项（生产指数、新订单指数、新出 口订单指数、积压订单指数、采购量指数、进口指数、原材料库存指数、从业人员指数和生产经营 活动预期指数）均出现不同程度的上行，上升幅度在0.2 ...

Group 1 - The report indicates that the bond market is expected to benefit from the inflow of risk-averse funds, with long-term interest rates slightly rising and short-term rates slightly falling [4][20][10] - The A-share market is experiencing a cautious upward trend, with the volatility of major indices at historical lows, suggesting that investors should be wary of potential increases in volatility [25][11] - The report highlights that the U.S. stock market is likely to continue its consolidation phase, with a focus on potential buying opportunities following a recession narrative [32][12] Group 2 - The report notes that the onshore RMB has depreciated against the USD, but is expected to appreciate towards 7.1, influenced by positive developments in China-US trade relations [6][37] - The commodity market is currently in a bearish trend, with the Wenhua Commodity Index hitting a new low, and investors are advised to adopt a cautious stance [40][41] - Key domestic policies include a call to resist "price war" competition in the automotive sector and a decline in the Caixin China Manufacturing PMI, indicating economic contraction [46][7]